Walking a Tightrope: Dosage Modifications and Treatment Outcomes of All-Trans-Retinoic Acid, Arsenic Trioxide, and Daunorubicin for High-Risk Acute Promyelocytic Leukemia

PURPOSE: The use of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) in the treatment of low- and intermediate-risk acute promyelocytic leukemia (APL) is the standard of care. We report the combined use of ATRA, ATO, and daunorubicin (DNR) in patients newly diagnosed with high-risk APL. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Danthala, Madhav, Golamari, Krishna Reddy, Seshachalam, Arun, Mikkilineni, Anupama, Chappidi, Sitalata, Mekala, Mahesh Babu, Elangovan, Vidhubala, Chinnakali, Palanivel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713580/
https://www.ncbi.nlm.nih.gov/pubmed/33201743
http://dx.doi.org/10.1200/GO.20.00226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713580/
https://www.ncbi.nlm.nih.gov/pubmed/33201743
http://dx.doi.org/10.1200/GO.20.00226

Ejemplares similares